This article has Open Peer Review reports available.
Adrenocortical cancer: mortality, hormone secretion, proliferation and urine steroids – experience from a single centre spanning three decades
© Calissendorff et al. 2016
Received: 10 July 2015
Accepted: 10 March 2016
Published: 17 March 2016
Adrenocortical carcinoma (ACC) is a rare malignant disease with a poor prognosis. Our aims were to study survival and to explore prognostic markers.
We retrospectively investigated the medical records of all 50 ACC patients at a single centre diagnosed between 1985 and 2012 and followed them up until 31/12/2014.
Of this cohort, twenty six (52 %) were females. Adrenalectomy was performed in 48 patients (96 %), and twenty seven (54 %) were treated with adjuvant cytotoxic agents. The tumor sizes ranged from 6 to 20 cm. Overall survival time was 5.5 years (0.3–19.8), the two and five-year survival was 64 and 40 %, respectively. In ENSAT stage II 25/48 patients had a median survival of 7.0 years (0.7–15.5), in stage III 8/48 this was 1.9 (0.4 – 19.8), and in stage IV 15/48 it was 1.2 (0.3–3.6) years. Seventeen patients (34 %) were still alive at the end of 2014. The total follow-up time was 8.4 (0.3–19.8) years. Cell proliferation measured with Ki-67 had a median value of 15 % (2–80) and the urinary steroid profile was clearly pathologic in 29 of 43 (67 %) tested patients. The proliferation index did not significantly predict mortality (Ki-67 ≤ 10 vs. >10 %, 9.0 vs. 3.2 years, P = 0.0833), but resection margins did (R1 vs. R2, P = 0.0066; R0 vs. R2, P < 0.0001). The urinary steroid profile did not predict mortality (normal vs. pathologic urine profile: median survival 6.6 vs. 3.3 years, P = 0.261).
The prognosis was generally poor and macroscopically positive resection margins resulted in a worse prognosis. However, some patients were still alive many years following primary surgery with no sign of residual disease.
Adrenocortical carcinoma (ACC) is a rare malignant disease with a poor prognosis. The annual incidence has been estimated to be between 0.5 and 2 cases per million people . It typically occurs during late middle age, but onset can also occur at a younger age. Symptoms can vary from abdominal pain and fatigue to hormonal symptoms if the tumor is actively secreting steroids, most commonly cortisol. ACC can also be found accidentally as an adrenal incidentaloma . Computed tomography (CT) usually shows a large, often more than 5 cm, tumor in one of the adrenal glands. Treatment, which in a few cases can induce cure, is radical surgery . Chemotherapy is often used. Mitotane has often been used alone or previously in combination with streptozotocin . A combination with etoposide, doxyrubicin and cisplatin on top of mitotane has been proposed as first-line therapy following a large prospective randomized controlled trial . Radiotherapy and targeted therapy is currently in clinical studies and has been tried in advanced disease . Control of hormonal secretion is vital. Close follow-up is mandatory with repeated radiology, and in case of endocrine hyper-secretion also of blood and urine markers.
In recurrent disease repeated surgical resection of loco-regional disease is an option in selected patients . The best prognostic factor after repeated surgery was time to first recurrence and radical surgery .
In recent publications median overall survival has in large cohorts been 35 to 38 months [8, 9], or a 5-year survival of 40 % in ENSAT stage III or 27.6 % in stage IV . However, there are difficulties in deciding the malignant potential in individual tumors. Cell proliferation, gene analysis, size, hormonal activity, tumor stage and grade as well as the age of the patient and the pattern of urinary steroids are all factors which have been claimed to be of value in determining the prognosis [11–13]. Gene profiling of tumours could differentiate and identify two types of ACC with different prognosis, and the combined expression of BUB1B and PINK1 was the best predictor of overall survival . The proliferative activity measured by immunostaining with the antibody MiB-1 can help to distinguish benign adrenocortical adenoma (ACA) from ACC . The index is calculated by counting the percentage of positive nuclei in 1000 cells in hot spots. High proliferation in adrenocortical neoplasm can be an indicator of worse prognosis , especially if Ki-67 is >4 %  or >10 % . However, long-term assessment on Ki-67 as a prognostic marker has previously only occasionally been referred to in ACC [18, 19], but Beuschlein et al. recently found Ki-67 to be the best prognostic marker for recurrence-free and overall survival in a large cohort from three European countries .
Urinary steroid profile (USP) may also be used in the assessment of ACC tumor activity and in the follow-up to find recurrent disease [20, 21], but no long-term investigations of this as a prognostic marker has been published. Different urinary steroids can be measured with gas chromatography–mass spectrometry , or by more rapid profiling of selected steroids by liquid chromatography/tandem mass spectrometry , although this has been questioned , but further studies are required. In healthy individuals urinary steroids are dominated by metabolites of androgens and cortisol. In cortisol producing adenomas the same metabolites are also seen but the levels of cortisol metabolites are increased as are the tetrahydrocortisol - tetrahydrocortisone ratios . To distinguish ACC from Cushing’s syndrome, secretion from accidentally discovered incidentaloma, or congenital adrenal hyperplasia USP can be of value [24, 25].
In ACC there is a characteristic domination of precursor steroids, indicating an immature steroidogenesis. The measurement of USP can also discover steroid precursors in ACC that has been classified as hormonally inactive, based on work-up with routine serum and urine analysis. In the majority of patients with ACC raised levels of tetrahydro-11-deoxycortisol (THS), pregnanetriol and/or 3β-hydroxy-5-ene steroids are seen (which is an umbrella term for metabolites from dehydroepiandrosterone [DHA], pregn-5-ene 3β,20α-diol [pregnenolone] or pregn5-ene-3β,17α,20α-triol [17α-hydroxypregnenolone]). Androgen metabolites are also frequently elevated in ACC, demonstrated by Gröndal et al. who reported that 13/24 patients with ACC had elevated androsterone and/or etiocholanolone levels . However, normal USP can be found in ACC.
Our aims were to study clinical features, survival and different markers in a cohort with ACC from a single tertiary centre to explore which factors could be used to predict the prognosis and survival. Moreover, we wanted to explore the potential benefit of measuring USP.
All medical records of patients diagnosed with ACC from 1 January 1985 to 31 December 2012 at the Karolinska University Hospital in Stockholm, Sweden, were audited. Sixty-two patients were identified, however, 11 patients had been wrongly diagnosed and one was lost to follow-up due to emigration. Thus 50 patients remained in the follow-up analysis. All patients had ACC diagnosed based on a combination of tumour size, clinical status, endocrine evaluation, radiology, histopathology, metastases at diagnosis or at follow-up and USP. Five were not known to have ACC at the time of primary adrenalectomy. All patients were followed until 31/12 2014. Clinical outcomes, urine and blood laboratory tests, USP, imaging, histopathology, including tumour stage and proliferation index (Ki-67), and treatment were recorded. Functional status was determined by pre-operative measurements of cortisol (24 h-urine sample or serum after a 1 mg dexamethasone suppression test [DST]), aldosterone (plasma or 24 h-urine sample), catecholamine (24 h-urine sample)/metanephrines (plasma), and adrenal androgens (serum) together with clinical status. A pathologic USP was defined as an elevation more than three times the upper limit of normal compared to normal levels of androgens (androsterone, etiocholanolone) and/or cortisol metabolites and/or 3β-hydroxy-5-ene steroids. Patients with an intermediate USP were distinguished by up to three times the upper limit of the normal range for androgens and cortisol metabolites, resembling findings in adrenal Cushing’s syndrome. Survival was calculated from the date of surgery (and for those not having surgery from the date of diagnosis) to the date of death of any cause or if still alive to 31/12 2014. All data was retrieved from the electronic or microfilmed medical records, and the National Population Register was consulted to determine whether the person was still alive. Time to local recurrence was estimated from the date of first surgery to the date of the imaging revealing recurrence.
Resection margins at surgery were defined as: R0, no evidence of tumour; R1, microscopically positive; R2, macroscopically positive; RX, unknown. The ENSAT staging system was used as it is considered superior in ACC . The classification defines: stage I, ACC ≤5 cm in the largest diameter and confined to the adrenal gland; stage II, ACC >5 cm without extra-adrenal invasion; stage III, presence of positive lymph nodes, infiltration to the surrounding tissue, or vascular tumour extension; stage IV, distant metastasis.
The data analysis was made in GraphPad Prism version 6.0 (developed GraphPad Software, Inc.). Mean ± SD or median (range) was used when appropriate. All proportions were calculated discounting missing values. Survival was analyzed with the Kaplan-Meier technique and comparisons were made with the log-rank test. Patients who died without local recurrence were censored to the date of death and patients were censored to the last follow-up if local recurrence or death had not occurred. A confidence interval of 95 % was used. A P < 0.05 was considered significant, and when multiple comparisons were made correction according to the Bonferroni principle was performed.
Background information in 50 patients with ACC
Hormone secreting tumor
37/45 (82 %)
Non secreting tumor
8 (18 %)
Missing hormone samples
5 (10 %)
Pathologic urine pattern
29/43 (67 %)
Tumor weight g
2 (4 %)
25 (50 %)
8 (16 %)
15 (30 %)
At the time of diagnosis 11/45 (22 %) had a normal endocrine work-up (excluding USP) in urine and serum, including dexamethasone suppression test. Not all cases were tested completely, thus of assessable patients 26/37 (70 %) had signs and biochemical findings suggestive of hypercortisolism, 2/36 (6 %) findings of concomitant elevation of catecholamines (urinary noradrenaline 842 nmol/L, normal < 400, and plasma normetanephrine 1.3 nmol/L, normal <0.6, respectively), and 4/26 (15 %) with hyperaldosteronism (all had more than double the upper reference limit of plasma aldosterone and urinary aldosterone with hypokalaemia and low renin). Two patients had polycythemia with haemoglobin of 180 and 235 g/L, respectively, the former of these two had an otherwise normal endocrine work-up and the latter, a woman, had an elevated testosterone level (14 nmol/L, normal <3). In all, eight had an excess of androgens measured with testosterone and/or DHEAS, five of whom were women. Of those with androgen excess, other endocrine dysfunctions were found in five cases. In total 37/45 (82 %) of all patients had endocrine disruption and only 8/45 (18 %) had a normal biochemistry. There was missing or incomplete laboratory data in five cases (10 %).
Urine steroid profile in 43 patients with adrenocortical cancer
Proliferation was measured with Ki-67 since 1993 (n = 32), and showed a mean of 18 ± 15.5 % and a median of 15 % (2–80 %). Weiss scores were not possible to analyse due to few reports.
Of the total, 48/50 (96 %) of the patients had adrenalectomy performed. Two patients, aged 42 and 56 years respectively, did not have adrenalectomy due to widespread metastatic disease and poor clinical status. One of these two received mitotane alone, the other mitotane in combination with etoposide, doxorubicin and cisplatin. The survival time was 9 and 18 months, respectively. At the time of primary surgery 10/48 (21 %) had known metastatic disease. These were operated on with a debulking intention. A further three cases displayed metastases at the time of surgery. Adjuvant cytotoxic agents were used within three months after surgery in 27/50 (54 %): 12 with mitotane alone (stage II: n = 6, stage III: n = 2, stage IV: n = 4), 10 with mitotane and streptozotocin (stage II: n = 5; stage III: n = 1; stage IV: n = 5), and five with mitotane, etoposide, doxorubicin and cisplatin (stage II: n = 2; stage IV: n = 3). During follow-up an additional nine patients with disseminated disease received chemotherapy, three with streptozotocin, three with streptozotocin and mitotane, and three with the combination of mitotane, etoposide, doxorubicin and cisplatin. Eight had repeated surgery due to metastatic disease.
Time to recurrence in the 25 patients in stage II with unknown metastatic disease at initial surgery was 1.5 years (0.2–9.0). At last follow-up 17 (34 %) patients were still alive. Of these nine (53 %) had been treated with cytotoxic agents whereas eight (47 %) been treated with adrenalectomy only. In patients who sought medical care with malignant symptoms 5/7 (71 %) were survivors at last follow-up, and of those with predominantly endocrine symptoms 5/19 (26 %) were still alive, however this was not statistically significant (P = 0.069). Eight patients (16 %) survived 10 years or more.
In this cohort of patients with ACC diagnosed during three decades we found a generally poor prognosis, but some were still alive without any residual disease after 19 years. Those who achieved better prognosis had been treated with radical R0 adrenalectomy, and R1 resection was also superior to R2. A normal USP compared to a pathologic pattern indicated a prolonged survival period greater than four years but this was not significant, possibly due to the limited number of ACC patients. There was also a tendency for patients without initial endocrine symptoms to have a more favourable prognosis.
The patients’ median age of 59 years is in accordance with the usual finding that the presentation age of ACC is in the fifth to sixth decade of life . We also found hormonal dysfunction in 82 %, or in 93 % if urine steroid measurements were added, which is double the frequency found by others , but is similar to a recent review . Our patients with ACC had a 5-year survival of 40 %. This is slightly more favourable than what has been reported in most previous and recent ACC series [8, 9, 29], but in line with the publication by Tran et al. . ENSAT stage was clearly associated with prognosis in the present cohort, corroborating previous investigations [8, 9, 30].
The Ki-67 value ≤10 % had an implication for survival together with macroscopically radical adrenalectomy. However, in this group of patients followed for a long time the survival in patients with a Ki-67 > 10 % was not statistically different from those with lower proliferating tumours. Some of the patients with clearly elevated Ki-67 had a rapid progression of the disease as 10/20 died within 5 years (Fig. 5). Of those surviving longer the impact of Ki-67 was apparently less. The most appropriate Ki-67 cut-off level needs further investigation as Morimoto et al. found 7 % to best predict disease-free survival , while McNicol et al. used >3 % and related this to prolonged disease-free survival . However, the latter study could not relate this to improved overall survival; probably due to lack of power as only 14 ACC patients were included. Higher cut-off levels has also been applied as <20, 20–50, and >50 % to estimate prognosis and Ki-67 was found to be the best marker for overall survival, superior to mitotic count and the mitosis specific antibody phospho-histone H3 . Beuschlein et al. recently reported on a large multi-centre cohort of patients with ACC where Ki-67 was the best prognostic maker for overall survival when dividing the cohort into <10, 10–19 and ≥20 % . Our findings are thus different from Beuschlein et al., which could be explained by differences in cohorts, but more probably is due to the limited number of ACC in our study. In the future tumour grade , and other prognostic markers may be of value in the prognostic appraisal such as gene profiling , steroidogenic factor 1 (SF-1) or β-Catenin .
A recent review stated that there was an area of uncertainty as to whether urinary gas chromatography–mass spectrometry steroid profile was of value or not . We found that those with normal USP had a better prognosis compared with those with pathological USP, and those with suspected pathological USP had a prognosis in between. However, these findings were not significant possibly due to the limited number of cases and USP should be investigated in larger multi-centre cohorts of ACC. USP could also potentially be used as a tool to discover recurrence.
Interestingly we found two patients also had neurofibromatosis. Previously only nine patients with ACC have been found to also have neurofibromatosis in the literature and recently a novel germline frame shift mutation (c.5452_5453delAT) in exon 37 of the NF1 gene was described in one such patient .
We do not believe any benign adenoma with a normal USP may have been misdiagnosed as ACC as histopathology and other examinations clearly indicated ACC. It will be interesting to see if the recently introduced urine steroid metabolomics analysis, reported to give a sensitivity and specificity of 88 % for discriminating benign adenoma from ACC , will be able to predict survival in ACC.
Surprisingly, age did not have a great impact on survival. To some extent this could be explained by the fact that only 16 % of our participants were <40 years of age.
Adrenalectomy is the only possible cure in ACC . However, the use of adjuvant therapy has once again increased in popularity , even though the evidence is still not conclusive. In our cohort 54 % had received adjuvant therapy, all with mitotane, some with streptozotocine, but it is unclear if they had a better prognosis. Of the 17 surviving patients at last follow-up, nine had been treated with adjuvant chemotherapy, whereas eight had adrenalectomy only. Thus adrenalectomy plus adjuvant chemotherapy did not seem superior to adrenalectomy alone. However, there may be a bias as it could be suspected that patients with more advanced disease more often received mitotane and/or other cytotoxic agents, but this could not be decided due to the limited number of participants.
This was a retrospective investigation with its limitations. The main limitation is the number of cases making it difficult to achieve significant results. However, since ACC is a rare disorder very few centres will have large numbers, thus multicenter and multinational studies are usually necessary to increase the number of ACC cases. Moreover, during these three decades the diagnostic and therapeutic methods changed which may have influenced the results. Some data were missing in a few patients concerning initial biochemical screening, in some cases due to the fact that the tumour type was not known at the time of surgery. The limited number of participants made subgroup analysis dependent on the year of diagnosis, meaningless. Also we could not assess Weiss score in a sufficient number of patients. A strength of the study is that all patients were well characterized and all could be followed-up.
ACC has diverse clinical outcomes. Prognosis is generally poor, but some patients remain alive even many years after primary surgery, and some of these have no sign of residual disease. Radical surgery in patients without metastases in tumours with a proliferation ≤ 10 % was favourable. Urinary steroid profile has a limited prognostic value, but can give further information on endocrine disruption not displayed by traditional biochemistry.
This investigation complies with the current laws in Sweden. The Regional Ethical Review Board in Stockholm, Sweden approved the study.
Availability of data
All data supporting the findings of this publication are presented in the main paper.
This study was supported by the Magn. Bergvalls Foundation, Karolinska Institutet and Stockholm County Council.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Terzolo M, Daffara F, Ardito A, Zaggia B, Basile V, Ferrari L, Berruti A. Management of adrenal cancer: a 2013 update. J Endocrinol Invest. 2014;37(3):207–17.View ArticlePubMedGoogle Scholar
- Patrova J, Jarocka I, Wahrenberg H, Falhammar H. Clinical Outcomes in Adrenal Incidentaloma - Experience from One Centre. Endocr Pract. 2015;21(8):870–7.Google Scholar
- Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, Wilander E, Oberg K, Eriksson B. Streptozocin and o, p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol. 2000;11(10):1281–7.View ArticlePubMedGoogle Scholar
- Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189–97.View ArticlePubMedGoogle Scholar
- Lebastchi AH, Kunstman JW, Carling T. Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art. J Oncol. 2012;2012:234726.View ArticlePubMedPubMed CentralGoogle Scholar
- Glover AR, Ip JC, Zhao JT, Soon PS, Robinson BG, Sidhu SB. Current management options for recurrent adrenocortical carcinoma. OncoTargets and therapy. 2013;6:635–43.PubMedPubMed CentralGoogle Scholar
- Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Ronchi C, Quinkler M, Waldmann J, Willenberg HS, Beuschlein F, Fottner C. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(1):181–91.View ArticlePubMedGoogle Scholar
- Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, Naing A, Sircar K, Wood CG. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol/European Federation of Endocrine Societies. 2013;169(6):891–9.View ArticleGoogle Scholar
- Else T, Williams AR, Sabolch A, Jolly S, Miller BS, Hammer GD. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2014;99(2):455–61.View ArticlePubMedPubMed CentralGoogle Scholar
- Tran TB, Liou D, Menon VG, Nissen NN. Surgical management of advanced adrenocortical carcinoma: a 21-year population-based analysis. Am Surg. 2013;79(10):1115–8.PubMedGoogle Scholar
- Miller BS, Gauger PG, Hammer GD, Giordano TJ, Doherty GM. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbeck's archives of surgery/Deutsche Gesellschaft fur Chirurgie. 2010;395(7):955–61.View ArticlePubMedGoogle Scholar
- Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2007;92(1):148–54.View ArticlePubMedGoogle Scholar
- Berruti A, Fassnacht M, Haak H, Else T, Baudin E, Sperone P, Kroiss M, Kerkhofs T, Williams AR, Ardito A. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol. 2014;65(4):832–8.View ArticlePubMedGoogle Scholar
- de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, Rene-Corail F, Dousset B, Bertagna X, Clauser E, Bertherat J. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol. 2009;27(7):1108–15.View ArticlePubMedGoogle Scholar
- Goldblum JR, Shannon R, Kaldjian EP, Thiny M, Davenport R, Thompson N, Lloyd RV. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod Pathol. 1993;6(6):663–8.PubMedGoogle Scholar
- Vargas MP, Vargas HI, Kleiner DE, Merino MJ. Adrenocortical neoplasms: role of prognostic markers MIB-1, P53, and RB. Am J Surg Pathol. 1997;21(5):556–62.View ArticlePubMedGoogle Scholar
- Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, Libe R, Ardito A, Al Ghuzlan A, Quinkler M. Major prognostic role of ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab. 2015;100(3):841–9.View ArticlePubMedGoogle Scholar
- Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Marshall D, Dudas M, Cordon-Cardo C, Jaques DP, Brennan MF. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol. 2002;20(4):941–50.View ArticlePubMedGoogle Scholar
- Morimoto R, Satoh F, Murakami O, Suzuki T, Abe T, Tanemoto M, Abe M, Uruno A, Ishidoya S, Arai Y. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J. 2008;55(1):49–55.View ArticlePubMedGoogle Scholar
- Minowada S, Kinoshita K, Hara M, Isurugi K, Uchikawa T, Niijima T. Measurement of urinary steroid profile in patients with adrenal tumor as a screening method for carcinoma. Endocrinol Jpn. 1985;32(1):29–37.View ArticlePubMedGoogle Scholar
- Grondal S, Eriksson B, Hagenas L, Werner S, Curstedt T. Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma. Acta Endocrinol. 1990;122(5):656–63.PubMedGoogle Scholar
- Soldin SJ, Soldin OP. Steroid hormone analysis by tandem mass spectrometry. Clin Chem. 2009;55(6):1061–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Krone N, Hughes BA, Lavery GG, Stewart PM, Arlt W, Shackleton CH. Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS). J Steroid Biochem Mol Biol. 2010;121(3–5):496–504.View ArticlePubMedPubMed CentralGoogle Scholar
- Falhammar H, Thoren M. An 88-year-old woman diagnosed with adrenal tumor and congenital adrenal hyperplasia: connection or coincidence? J Endocrinol Invest. 2005;28(5):449–53.View ArticlePubMedGoogle Scholar
- Falhammar H. Non-functioning adrenal incidentalomas caused by 21-hydroxylase deficiency or carrier status? Endocrine. 2014;47(1):308–14.View ArticlePubMedGoogle Scholar
- Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budaus L, Shariat SF, Guazzoni G, Montorsi F. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer. 2010;46(4):713–9.View ArticlePubMedGoogle Scholar
- Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2009;23(2):273–89.View ArticlePubMedGoogle Scholar
- Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(12):4551–64.View ArticlePubMedGoogle Scholar
- Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91(6):2027–37.View ArticlePubMedGoogle Scholar
- Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, Van de Poll-Franse LV, Haak HR. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579–86.View ArticlePubMedGoogle Scholar
- McNicol AM, Struthers AL, Nolan CE, Hermans J, Haak HR. Proliferation in Adrenocortical Tumors: Correlation with Clinical Outcome and p53 Status. Endocr Pathol. 1997;8(1):29–36.View ArticlePubMedGoogle Scholar
- Duregon E, Molinaro L, Volante M, Ventura L, Righi L, Bolla S, Terzolo M, Sapino A, Papotti MG. Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma. Mod Pathol. 2014;27(9):1246–54.View ArticlePubMedGoogle Scholar
- Papotti M, Duregon E, Volante M, McNicol AM. Pathology of the adrenal cortex: a reappraisal of the past 25 years focusing on adrenal cortical tumors. Endocr Pathol. 2014;25(1):35–48.View ArticlePubMedGoogle Scholar
- Menon RK, Ferrau F, Kurzawinski TR, Rumsby G, Freeman A, Amin Z, Korbonits M, Chung TT. Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis. Endocrinol Diabetes Metab case reports. 2014;2014:40074.Google Scholar
- Arlt W, Biehl M, Taylor AE, Hahner S, Libe R, Hughes BA, Schneider P, Smith DJ, Stiekema H, Krone N. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab. 2011;96(12):3775–84.View ArticlePubMedPubMed CentralGoogle Scholar